This site is intended for health professionals only

Published on 22 June 2007

Share this story:
Twitter
LinkedIn
Share
RELATED ARTICLES
Superiority of afatinib over comparator chemotherapy
Physically active have reduced risk of prostate cancer
Crohn’s disease study reveals potential for personalised treatment
Management of chronic pain
Aromatase inhibitors as adjuvant therapy in postmenopausal women with early breast

US go-ahead for Exforge

teaser

Novartis has received US approval for Exforge



Most read

1
Feedback: Automation systems in your hospital
2
Helapet introduce new, improved 20mm Vented Vial Adapter
3
Janssen-Cilag’s Stelara approved by NICE
4
Merck agrees huge Vioxx settlement
5
Encouraging results for SLE treatment



Latest Issue

Read the latest issue >
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
Share this story:
Twitter
LinkedIn
Share
RELATED ARTICLES
FDA updates Glivec label for gastrointestinal tumours
An aroma sprayed up the nose could help treat anorexia
Bone studies “wrong for 70 years”
Improving adherence to oral cancer treatments
NICE recommends Verzenios with an aromatase inhibitor (AI) to treat metastatic breast cancer